XCell Therapeutics Inc is a Korea-based company primarily engaged in the manufacture and distribution of cell culture mediums. The Company is mainly engaged in the provision of dermal papilla cells (DPC), keratinocytes, exosomes and other dedicated mediums. Additionally, the Company is engaged in the manufacture and distribution of virus transport mediums. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/09/26	KRW 1,018.00	+0.10%	21,124
15/09/26	KRW 1,017.00	+0.99%	65,854
14/09/26	KRW 1,007.00	-0.89%	62,569
11/09/26	KRW 1,016.00	+1.60%	45,875
10/09/26	KRW 1,000.00	0.00%	53,605

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 16/09/2026			5-day change	1st Jan Change
1,018.00 ^KRW	+0.10%		+0.10%	-38.71%

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
22/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI

Market Cap	17.61B 12.87M 11.15M 10.54M 9.57M 17.93M 1.23B 18.04M 126M 48.62M 626M 48.34M 47.27M 2B	P/E 2024	-4.26x	P/E 2025	-1.77x
Enterprise Value	16.19B 11.83M 10.25M 9.69M 8.8M 16.49M 1.13B 16.59M 116M 44.7M 576M 44.44M 43.45M 1.83B	EV / Sales 2024	21.3x	EV / Sales 2025	14x
Free-Float	88.23%	Yield 2024 *	-	Yield 2025	-

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
22/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI
16/07/24	Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut	MT
08/07/24	Xcell Therapeutics Inc. has completed an IPO in the amount of KRW 16.18 billion.	CI

1 day	+0.10%
1 week	+0.10%
Current month	-14.60%
1 month	-21.75%
3 months	-27.65%
6 months	-28.11%
Current year	-38.71%

Xcell Therapeutics Inc. Stock

Stocks

A373110

KR7373110006

Pharmaceuticals

Valuation: Xcell Therapeutics Inc.

Chart: Xcell Therapeutics Inc.

Latest news: Xcell Therapeutics Inc.

News in other languages: Xcell Therapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Xcell Therapeutics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	951	1,046
1 month	951	1,482
Current year	951	2,050
1 year	951	4,035
3 years	951	12,900
5 years	951	12,900
10 years	951	12,900

Manager	Title	Age	Since
U-Ri Lee CEO	Chief Executive Officer	54	01/09/2016
Soo-Rim Oh COO	Chief Operating Officer	65	-
Hae-Min Jeong CTO	Chief Tech/Sci/R&D Officer	40	-

Director	Title	Age	Since
U-Ri Lee BRD	Director/Board Member	54	01/09/2016
Hae-Min Jeong BRD	Director/Board Member	40	-
Mahn-Soon Hwang BRD	Director/Board Member	56	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XCELL THERAPEUTICS INC.	+0.10%	+0.10%	-64.53%	-	12.91M
ELI LILLY AND COMPANY	+0.15%	+1.21%	+48.79%	+97.65%	1,013B
JOHNSON & JOHNSON	+0.03%	+0.07%	+51.47%	+65.55%	644B
ABBVIE INC.	-0.20%	+4.62%	+21.39%	+72.57%	465B
ROCHE HOLDING AG	+0.53%	+4.26%	+40.29%	+38.70%	352B
NOVARTIS AG	+0.39%	+2.35%	+17.96%	+23.87%	264B
ASTRAZENECA PLC	+0.17%	+2.19%	+6.33%	+10.93%	253B
AMGEN INC.	+0.19%	-3.81%	+37.81%	+44.35%	203B
NOVO NORDISK A/S	-1.20%	-6.64%	-23.23%	-59.10%	188B
GILEAD SCIENCES, INC.	+0.94%	+1.39%	+33.21%	+95.16%	181B
Average	+0.11%	-0.80%	+16.95%	+43.30%	356.37B
Weighted average by Cap.	+0.11%	+0.01%	+34.33%	+59.67%

	2024	2025
Net sales	1.93B 1.41M 1.23M 1.16M 1.05M 1.97M 136M 1.98M 13.82M 5.34M 68.79M 5.31M 5.19M 219M	1.95B 1.42M 1.23M 1.17M 1.06M 1.99M 137M 2M 13.93M 5.38M 69.31M 5.35M 5.23M 221M
Net income	-9.54B -6.98M -6.04M -5.71M -5.19M -9.72M -669M -9.78M -68.2M -26.35M -339M -26.2M -25.62M -1.08B	-10.93B -7.99M -6.92M -6.54M -5.94M -11.13M -766M -11.2M -78.09M -30.18M -389M -30M -29.34M -1.24B
Net Debt	-3.1B -2.27M -1.96M -1.86M -1.69M -3.16M -217M -3.18M -22.16M -8.56M -110M -8.51M -8.32M -351M	-1.42B -1.04M -899K -850K -771K -1.45M -99.52M -1.45M -10.14M -3.92M -50.48M -3.9M -3.81M -161M